Ghayas C Issa
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ghayas C Issa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04216563 · ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorM.D. Anderson Cancer Center · terminated · Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 07:50 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J Med · 2024156 citationsRCR 21.1
- 58 citationsRCR 2.2
- Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.Lancet Haematol · 202419 citationsRCR 2.6
- Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.Cancer · 202415 citationsRCR 2.1
- 14 citationsRCR 7.0
- Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.Cancer · 202410 citationsRCR 1.4
- A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.Am J Hematol · 202410 citationsRCR 1.2
- Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.Clin Lymphoma Myeloma Leuk · 2026